$1.70
8.11% day before yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US8723811084
Symbol
TELA

TELA Bio Inc Stock price

$1.70
+0.72 73.47% 1M
-1.07 38.63% 6M
-1.32 43.71% YTD
-3.83 69.26% 1Y
-16.59 90.71% 5Y
-11.65 87.27% 10Y
-11.65 87.27% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.15 8.11%
ISIN
US8723811084
Symbol
TELA
Sector

Key metrics

Market capitalization $67.24m
Enterprise Value $65.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.92
P/S ratio (TTM) P/S ratio 0.94
P/B ratio (TTM) P/B ratio 3.71
Revenue growth (TTM) Revenue growth 12.80%
Revenue (TTM) Revenue $71.22m
EBIT (operating result TTM) EBIT $-39.76m
Free Cash Flow (TTM) Free Cash Flow $-37.65m
Cash position $42.83m
EPS (TTM) EPS $-0.95
P/E forward negative
P/S forward 0.78
EV/Sales forward 0.76
Short interest 2.10%
Show more

Is TELA Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

TELA Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a TELA Bio Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a TELA Bio Inc forecast:

Buy
80%
Hold
20%

Financial data from TELA Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
71 71
13% 13%
100%
- Direct Costs 24 24
20% 20%
33%
48 48
9% 9%
67%
- Selling and Administrative Expenses 78 78
0% 0%
110%
- Research and Development Expense 8.96 8.96
10% 10%
13%
-39 -39
13% 13%
-54%
- Depreciation and Amortization 1.05 1.05
28% 28%
1%
EBIT (Operating Income) EBIT -40 -40
12% 12%
-56%
Net Profit -43 -43
8% 8%
-61%

In millions USD.

Don't miss a Thing! We will send you all news about TELA Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TELA Bio Inc Stock News

Neutral
GlobeNewsWire
8 days ago
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TE...
Neutral
GlobeNewsWire
11 days ago
Based on market research, inguinal hernia repair is the most common type of hernia repair Based on market research, inguinal hernia repair is the most common type of hernia repair
Neutral
GlobeNewsWire
13 days ago
Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth
More TELA Bio Inc News

Company Profile

TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

Head office United States
CEO Antony Koblish
Employees 209
Founded 2012
Website www.telabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today